MetaCap

Kiora Pharmaceuticals (KPRX) vs Skye Bioscience (SKYE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Kiora Pharmaceuticals is the larger company by market cap ($3.2 million vs $3.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

KPRX-71.53%SKYE-57.58%
+6%-35%-75%
Oct 7, 20261 yearNov 20, 2026
KPRX-71.65%SKYE-58.58%
+4%-36%-75%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

KPRX versus SKYE key metrics
MetricKPRXSKYE
Share price$0.7202$0.70
Market cap$3.19M$3.10M
1-day change-12.28%-11.03%
YTD return-63.44%—
1-year return-61.49%—
5-year return-99.87%—
EPS (TTM)$-2.72$-7.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-10.84M$-55.92M
52-week high$2.91$11.04
52-week low$0.72$0.484
Distance from 52-week high-75.25%-93.66%
Analyst consensusnonenone
Avg. price target upside+1566.20%+9614.29%
Average volume35.23K88.19K
Shares outstanding4.42M4.42M
Employees132
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Kiora Pharmaceuticals

KPRX stock →

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Skye Bioscience

SKYE stock →

Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

KPRX vs SKYE FAQ

Which is bigger, Kiora Pharmaceuticals or Skye Bioscience?

Kiora Pharmaceuticals (KPRX) is larger, with a market capitalization of $3.19M compared with $3.10M for Skye Bioscience (SKYE).

Are Kiora Pharmaceuticals and Skye Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons